Skip to main content

Advertisement

Table 4 Affordability for eight major health conditions

From: Navigating through the maze of pricing and affordability of branded pharmaceuticals in the midst of the financial crisis: a comparative study among five European recession countries, from a Cyprus perspective

Condition Products Strength Price (Eur) (Price calculated per monthly basis for each denoted strength )
Italy Greece Portugal Cyprus Spain
Dyspepsia Esomeprazolea 20 mg 7,08 10,81 8,8 18,63 6,3
Diabetes Januvia 100 mg 59,22 50,22 50,53 58,37 55,72
Osteoarthritis Etoricoxiba 90 mg 17,84 14,02 16,32 23,1 20,32
Blood pressure Candesartan 16 mg 11,95 12,36 22,62 28,8 25,76
Hypercholesterolemia Rosuvastatin 5 mg 22,49 11,27 17,01 28,74 18,9
Depression Escitaloprama 10 mg 24,97 13,23 11,52 15,39 16,66
Osteoporosis Zolendronic acidb 5 mg/100 ml 557,36 451,27 344,21 590,98 422,65
Asthma Salmeterol/Fluticasone 25/50 μg 41,22 34,39 36,15 41,33 39,6
  Lowest monthly wage   992.4 [15] 878 565 870 748
  Catastrophic expenditure threshold   942.8 834 536 826 710
  1. aFor Esomeprazole, Etoricoxib and Escitalopram, the cost was calculated based on consumption for 28 days, thus calculating the cost of two packages
  2. bFor Zolendronic acid, the monthly cost was calculated, since this product is administered yearly